Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in Non-Constipation IBS
NCT06221111Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rimegepant in irritable bowel syndrome (IBS), sponsored by Mayo Clinic. Started Jun 2024; status: completed.
02
Drugs
rimegepant
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06221111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221111.